NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA). The conference will take place October 21-24, 2010, at the Vancouver Convention and Exhibition Centre in Vancouver, British Columbia, Canada.
The presentations will include new data from clinical and preclinical studies of NovaBay's lead Aganocide® compound.
Ron Najafi, chairman and CEO of NovaBay, said, "These presentations illustrate NovaBay's ongoing efforts to address the growing global crisis of antibiotic resistance by developing and commercializing an extensive pipeline of first-in-class, non-antibiotic anti-infective compounds that are designed to treat infections without the use of antibiotics."
NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical and clinical programs. Clinical programs using the company's lead Aganocide drug candidate are under way for the treatment of impetigo, a highly contagious skin infection, for the prevention of urinary catheter encrustation and blockage and for the treatment of conjunctivitis or pink eye.
Poster session details are as follows:
In vitro Evaluation of Antifungal Activity of NVC-422 Using a Novel Cadaver Nail Model
A Pilot Study to Evaluate the Safety and Efficacy of NVC-422 Topical Gel in Impetigo, Including MRSA
New antibiotic compound emerges as strong candidate in the fight against MRSA